盐酸拉贝洛尔片致妊娠期高血压伴银屑病患者皮疹加重1例分析

doi:10.19803/j.1672-8629.20220642

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (9): 1060-1063.
DOI: 10.19803/j.1672-8629.20220642

盐酸拉贝洛尔片致妊娠期高血压伴银屑病患者皮疹加重1例分析

张晴¹, 朱磊², 蔺存莲², 解沛涛¹, 杨俊丽¹, 苏长海^1,*

¹鄂尔多斯市中心医院药剂科,内蒙古鄂尔多斯 017000;
²鄂尔多斯市中心医院妇产科,内蒙古鄂尔多斯 017000

收稿日期:2022-11-04 出版日期:2023-09-15 发布日期:2023-09-14
通讯作者: ^*苏长海,男,博士,主任药师,临床药学及医院药学。E-mail: suchanghai0228@sina.cn
作者简介:张晴,女,硕士,主管药师,妊娠哺乳期用药及临床药学。
基金资助:
鄂尔多斯市卫生健康委员会医学重点学科建设项目（鄂卫健发〔2020〕230号）

Psoriasis aggravated by labetalol during pregnancy: a case report

ZHANG Qing¹, ZHU Lei², LIN Cunlian², XIE Peitao¹, YANG Junli¹, SU Changhai^1,*

¹Pharmacy Department of Ordos Central Hospital, Ordos Inner Mongolia 017000, China;
²Obstetrics and Gynecology Department of Ordos Central Hospital, Ordos Inner Mongolia 017000, China

Received:2022-11-04 Online:2023-09-15 Published:2023-09-14

摘要/Abstract

摘要： 目的探讨盐酸拉贝洛尔片治疗妊娠期高血压加重银屑病病例,为临床安全用药提供参考。方法分析1 例盐酸拉贝洛尔片加重妊娠期高血压伴银屑病的治疗过程,结合文献资料,探讨盐酸拉贝洛尔片引起皮疹的作用机制及特点。结果盐酸拉贝洛尔片加重妊娠期高血压伴银屑病病情,使患者皮疹症状加重。结论特殊人群银屑病的治疗过程中需敏锐识别药品不良反应,β受体阻滞剂对于伴银屑病的妊娠期高血压患者要谨慎使用。

关键词: 盐酸拉贝洛尔片, 妊娠, 高血压, 银屑病, 药品不良反应

Abstract: Objective To study the applicability of labetalol hydrochloride tablets in the treatment of gestational hypertension with psoriasis so as to provide reference for safe clinical use of the drug. Methods One case of gestational hypertension with psoriasis aggravated by labetalol hydrochloride tablets in our hospital was analyzed. The mechanism of action and characteristics of skin rash caused by labetalol hydrochloride tablets were explored by referring to literature. Results Labetalol hydrochloride tablets aggravated psoriasis in this patient with hypertension during pregnancy. Conclusion Clinical pharmacists should be sensitive to the adverse drug reactions in the treatment of psoriasis in special populations. Beta-blockers should be used with caution in patients with hypertension complicated with psoriasis during pregnancy.

Key words: labetalol hydrochloride tablets, pregnancy, hypertension, psoriasis, adverse drug reaction

中图分类号:

张晴, 朱磊, 蔺存莲, 解沛涛, 杨俊丽, 苏长海. 盐酸拉贝洛尔片致妊娠期高血压伴银屑病患者皮疹加重1例分析[J]. 中国药物警戒, 2023, 20(9): 1060-1063.

ZHANG Qing, ZHU Lei, LIN Cunlian, XIE Peitao, YANG Junli, SU Changhai. Psoriasis aggravated by labetalol during pregnancy: a case report[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1060-1063.

参考文献

[1] REGITZ-ZAGROSEK V, ROOS-HESSELINK JW, BAUERSACHS J, et al.2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy[J]. European Heart Journal, 2018, 39(34): 3165-3241.
[2] American College of Obstetricians and Gynecologists. ACOG practice bulletin no.202 gestational hypertension and preeclampsia[J]. Obstet Gynecol, 2019, 133: e1-e25.
[3] HAO H, GU X, CAI Y, et al.The influence of pregnancy-induced hypertension syndrome on the metabolism of newborns[J]. Translational Pediatrics, 2021,10(2): 296-305.
[4] AGRAWAL A, WENGER NK.Hypertension during pregnancy[J]. Current Hypertension Reports, 2020, 22(9): 1-9.
[5] QUINTARD B, CONSTANT A, BOUYSSOU-GAUTHIER ML, et al.Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: the QualiPso Questionnaire[J]. Acta Dermato-Venereologica, 2011, 91(6): 660-665.
[6] AUGUSTIN M, RADTKE MA.Quality of life in psoriasis patients[J]. Expert Review of Pharmacoeconomics & Outcomes Research, 2014, 14(4): 559-568.
[7] BALAK DM, HAJDARBEGOVIC E.Drug-induced psoriasis: clinical perspectives[J]. Psoriasis (Auckland, NZ), 2017, 7: 87-94.
[8] TSANKOV N, ANGELOVA I, KAZANDJIEVA J.Drug-induced psoriasis. recognition and management[J]. American Journal of Clinical Dermatology, 2000, 1(3): 159-165.
[9] BALAK DM, HAJDARBEGOVIC E.Drug-induced psoriasis: clinical perspectives[J]. Psoriasis (Auckl), 2017, 7: 87-94.
[10] GLASS LR, NGUYEN M, WINN BJ, et al.Timolol drops causing reversible psoriatic fingernail changes[J]. JAMA Ophthalmology, 2013, 131(9): 1134.
[11] WAQAR S, SARKAR PK.Exacerbation of psoriasis with beta-blocker therapy[J]. Canadian Medical Association Journal, 2009, 181(1-2): 60.
[12] GANGE RW, JONES EW.Bullous lichen planus caused by labetalol[J]. Br Med J, 1978, 1(6116): 816-817.
[13] FINLAY AY, WADDINGTON E.Cutaneous reactions to labetalol[J]. Br Med J, 1978, 1(6118): 987.
[14] MANCANO MA.Acute generalized exanthematous pustulosis due to labetalol[J]. Hosp Pharm, 2016, 51(6): 437-441.
[15] DIAO YH, LI B, WANG G.Advances in drug studies to induce and aggravate psoriasis[J]. The International Journal of Dermatology and Venereal Diseases(国际皮肤性病学杂志), 2016, 42(4): 219-221.
[16] ZHENG FY, WU Y, RAO YF, et al.The role of the Nobel assessment scale in the adverse drug reaction evaluation and example analysis[J]. Chinese Journal of Pharmacy(中国药学杂志), 2012, 47(8): 650-652.
[17] INGELFINGER FJ.The side effects of aspirin[J]. New England Journal of Medicine, 1974, 290(21): 1196-1197.
[18] CISEN. Instructions-Prednisone acetate tablets[EB/OL]. (2007-05-16)[2020-10-10]. http://ypk.39.net/728677/manual/.
[19] SALVI M,VANNUCCHI G,SBROZZI F, et al.Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report[J]. Thyroid, 2004, 14(8): 631-634.
[20] LI W, ZHENG LL, LI LM, et al.Analysis of adverse reactions of low molecular weight heparin drugs in pregnant women from 2018 to 2020 in a hospital[J]. Jiangxi Medicine(江西医药), 2022, 57(1): 92-94.
[21] ZHANG SS, SONG XF, LI M, et al.Meta-analysis of the association between psoriasis and adverse pregnancy outcomes[J]. The Chinese Journal of Dermatology(中华皮肤科杂志), 2020, 53(4): 299-302.
[22] JOHANSEN CB, EGEBERG A, JIMENEZ-SOLEM E, et al.Psoriasis and adverse pregnancy outcomes: a nationwide case-control study in 491, 274 women in Denmark[J]. JAAD International, 2022, 7: 146-155.
[23] XIE W, HUANG H, JI L, et al.Maternal and neonatal outcomes in pregnant women with psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Rheumatology (Oxford, England), 2021, 60(9): 4018-4028.
[24] WANG W, SUNG N, GILMAN-SACHS A, et al.T helper (th) cell profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh cells[J]. Frontiers in Immunology, 2020, 11: 2025.
[25] FIGUEIREDO AS, SCHUMACHER A.The T helper type 17/regulatory T cell paradigm in pregnancy[J]. Immunology, 2016, 148(1): 13-21.
[26] SZYMAŃSKA E, KISIELEWSKI R, KIERKUŚ J. Reproduction and pregnancy in inflammatory bowel disease - management and treatment based on current guidelines[J]. Journal of Gynecology Obstetrics and Human Reproduction, 2021, 50(3): 101777.
[27] FERREIRA C, AZEVEDO A, NOGUEIRA M, et al. Management of psoriasis in pregnancy - a review of the evidence to date[J]. Drugs Context, 2020, 9: 2019-11-6.
[28] GOTTLIEB AB, MEROLA JF, REICH K, et al.Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from exceed, a randomized, double-blind head-to-head monotherapy study[J]. Br J Dermatol, 2021, 185(6): 1124-1134.
[29] SHI DD, YANG FZ, ZHOU L, et al.Oral nifedipine vs intravenous labetalol for treatment of pregnancy-induced severe preeclampsia[J]. J Clin Pharm Ther, 2016, 41: 657-661.
[30] ACOG. Committee opinion no. 767: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period[J]. Obstet Gynecol, 2019, 133: e174-e180.
[31] ACOG. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222[J]. Obstet Gynecol, 2020, 135: e237-e260.
[32] WU HZ, CHENG Y, YU D, et al.Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials[J]. Hypertension in Pregnancy, 2022, 41(2): 126-138.

盐酸拉贝洛尔片致妊娠期高血压伴银屑病患者皮疹加重1例分析

Psoriasis aggravated by labetalol during pregnancy: a case report

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.